Saltar al contenido
Merck
  • A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia.

A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia.

Fertility and sterility (2004-06-15)
Andrea Lenzi, Paolo Sgrò, Pietro Salacone, Donatella Paoli, Barbara Gilio, Francesco Lombardo, Maria Santulli, Ashok Agarwal, Loredana Gandini
RESUMEN

To determine the efficacy of combined l-carnitine and l-acetyl-carnitine therapy in infertile males with oligo-astheno-teratozoospermia. Placebo-controlled double-blind randomized trial. University tertiary referral center. Sixty infertile patients (aged 20-40 years) with the following baseline sperm selection criteria: concentration, 10 to 40 x 10(6)/mL; forward motility, <15%; total motility, 10% to 40%; and atypical forms, <80%. Fifty-six patients completed the study. Patients were submitted to a combined treatment of l-carnitine (2 g/d) and l-acetyl-carnitine (1 g/d) or of placebo; the study design was 2 months' wash-out, 6 months of therapy or of placebo, and 2 months' follow-up. Variation in the semen parameters that were used for patient selection. Even though increases were seen in all sperm parameters after combined carnitine treatment, the most significant improvement in sperm motility (both forward and total) was present in patients who had lower initial absolute values of motile sperm (<4 x 10(6) forward or <5 x 10(6) total motile spermatozoa per ejaculate). Combined treatment with l-carnitine and l-acetyl-carnitine in a controlled study of efficacy was effective in increasing sperm motility, especially in groups with lower baseline levels.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
L-Carnitine inner salt, synthetic, ≥98%
Levocarnitine, European Pharmacopoeia (EP) Reference Standard